Although SiglecF–CD11c–CD11b+ macrophages, reflecting MoMs, showed no significant changes following MSC administration, intravenous MSCs significantly reduced the number of M2 MoMs in the BLM group. The gene discussed is ITGAX; the disease is Bloom syndrome.